| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-14 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-12 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-11 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-08 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |